|
|
Post by sla55 on Dec 6, 2021 7:51:40 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-winter-2021WESTLAKE VILLAGE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the Company’s Chief Executive Officer, Michael Castagna, PharmD, will be participating in a webcasted Fireside Chat discussing its vision for 2022 and Mr. Castagna and the Company’s Chief Financial Officer, Steven B. Binder will be conducting 1x1 virtual investor meetings. The webcasted Fireside Chat will be available for viewing at 11:00 AM ET on Monday, December 13, 2021, on the Company's website at investors.mannkindcorp.com/events-and-presentations. The webcast will also be archived and available for replay. To arrange a 1x1 meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at www.lythampartners.com/winter2021invreg.
|
|
|
|
Post by mymann on Dec 13, 2021 16:17:57 GMT -5
Did anyone listen to the pre recorded talk from Mike at Lytham Partners winter 2021 conference? Nothing new, only same crap.
|
|
|
|
Post by peppy on Dec 13, 2021 16:23:39 GMT -5
Did anyone listen to the pre recorded talk from Mike at Lytham Partners winter 2021 conference? Nothing new, only same crap. , listened and gave report on another thread. "Latham Partners conference 12/13/21 I listened to the presentation today and my main take away is that there won’t be any news to move the stock price before year end. - UT hasn’t resubmitted to the FDA yet - No news from RLS expected before EOY - Pipeline Updates are expected 1Q-2Q 2022 Overall positive presentation for 2022-2023 but I don’t expect much sp movement near term. I will listen to the replay tonight." |
|
|
|
Post by mymann on Dec 13, 2021 17:19:49 GMT -5
My bad, thanks.
|
|
|
|
Post by centralcoastinvestor on Dec 13, 2021 23:03:52 GMT -5
I was able to listen to today's Lytham Partners Fireside Chat. I thought it was a great interview. Here are my takeaways:
1. Mike was confident and relaxed. He has been like this in last several interviews.
2. Mike spoke about Tyvaso DPI and that he is confident that it will be approved by Summer 2022 or sooner. 3. Mentioned that MannKind and United have a very close relationship. He said they are working on other compounds and may announce what they are next year. 4. The pipeline is full. Mike is excited that they will have 3 to 5 "shots on goal" in the next couple of years. Talked about expanding Research and Development
5. Mike is most excited about Clofazimine. Going forward with both Nebulizer and DPI. Should see some readouts in 1st or 2nd quarter 2022 and maybe Phase 2 start 6. Working on formulations with other companies right now. No comment on when any announcements will be made. 7. Afrezza initiatives includes head to head comparison to pumps and Seeing Is Believing Pilot 8. MIDD pilot with FDA is exciting. This pilot program with FDA allows real world experience along with smaller studies to potentially help change dosing on the label. Potentially, this could change the current stupid dosing label on Afrezza. 9. Mike is excited about the Pediatrics Trial. 10 of 20 sites up and running. 9. Mike expecting some news in 2022 from RLS. Maybe begin Phase 2. 10. Chip shortage still hampering BluHale launch. 11. Key Issues for 2022 - a. Effects of Covid still hamper employee recruiting and retention. b. Looking for approval of Tyvaso DPI. c. Positive Clofazimine readout
Most companies hope for one or two good news story lines. MannKind has at least a half dozen. I continue to be amazed that Wall Street still misses the amazing MannKind story.
|
|
|
|
Post by mytakeonit on Dec 14, 2021 1:52:48 GMT -5
Who cares about Wall Street  Buy all the cheap shares you can !!! But, that's mytakeonit |
|
|
|
Post by MnkdWASmyRtrmntPlan on Dec 14, 2021 13:25:45 GMT -5
Thank you for that nice summary cci.
|
|
|
|
Post by mango on Dec 14, 2021 18:20:37 GMT -5
🥭 Tyvaso DPI approval summer 2022
🥭 Tyvaso DPI will have both PAH and ILD indications
🥭 Over $100M in annual royalties by year 2024
🥭 UT and MannKind will continue to explore additional collaboration pipeline candidates
🥭 UT cannot partner with another dry powder manufacturer for PAH—only MannKind
🥭 MannKind’s pipeline has a higher probability of success than failure compared to other companies
🥭 Clofazimine Phase 1 initiation around the new year
🥭 Clofazimine data early Q1/Q2
🥭 ZYESAMI Phase 1 initiation Q4 2022
🥭 Receptor Life Sciences Phase 1 has been INITIATED in Australia—will wrap up quickly
🥭 Receptor Life Sciences Phase 1 read out early 2022
🥭 Clofazimine DPI is in the works
🥭 Afrezza Primary Care Pilot initiated & ongoing
🥭 Afrezza is $35 for Medicare patients
🥭 MannKind is focused on increasing Afrezza awareness and scripts
🥭 Afrezza Seeing is Believing Campaign has LAUNCHED
|
|
|
|
Post by sellhighdrinklow on Dec 14, 2021 22:02:48 GMT -5
"Afrezza is $35 for Medicare patients"
Thank you, Mango. Can anybody else confirm the $35 for Medicare is accurate?
TYIA
|
|
|
|
Post by nylefty on Dec 15, 2021 1:19:06 GMT -5
"Afrezza is $35 for Medicare patients" Thank you, Mango. Can anybody else confirm the $35 for Medicare is accurate? TYIA There was a long thread about this last March. Basically, MannKind agreed to take part in a program that all the other drug companies with insulin drugs have been participating in since last Januarty first. They all agreed to a plan under which insulin drugs are available in some, but not all, Medicare Part D plans for $35 a month. But insurance companies don't have to particapate and some don't. As I wrote last March: I don't think it's a big deal at all. MannKind could have joined Big Pharma in this program this year or slashed prices on its own, but it didn't have the money to do that.
It may mean getting a lot more people on Afrezza next year, but at the cost of losing money on every prescription. That may be worth it in terms of getting the word out, but I see no reason for it to affect the stock price anytime this year. |
|
|
|
Post by mango on Dec 15, 2021 6:56:24 GMT -5
Has anyone noticed the Afrezza Healthcare Provider website lately?
Absolutely fantastic. I love the language we are using to showcase Afrezza and differentiate ourselves from the rest.
Website looks the best it ever has, IMO.
|
|
|
|
Post by sportsrancho on Dec 15, 2021 8:38:02 GMT -5
Has anyone noticed the Afrezza Healthcare Provider website lately? Absolutely fantastic. I love the language we are using to showcase Afrezza and differentiate ourselves from the rest. Website looks the best it ever has, IMO. How are they getting the providers to the website? |
|
|
|
Post by peppy on Dec 15, 2021 9:11:26 GMT -5
Has anyone noticed the Afrezza Healthcare Provider website lately? Absolutely fantastic. I love the language we are using to showcase Afrezza and differentiate ourselves from the rest. Website looks the best it ever has, IMO. How are they getting the providers to the website? Many times on the afrezza page that comes up, at the top of the page is a link for health care providers. afrezza.comthere it is on the top of the page, healthcare professional site. Providers know there are links to the professional sites on the medication website. Heck, I knew it.  |
|
|
|
Post by sportsrancho on Dec 15, 2021 9:26:58 GMT -5
How are they getting the providers to the website? Many times on the afrezza page that comes up, at the top of the page is a link for health care providers. afrezza.comthere it is on the top of the page, healthcare professional site. Providers know there are links to the professional sites on the medication website. Heck, I knew it. Well heck I knew it too. But how are they getting it to the right audience? |
|
|
|
Post by peppy on Dec 15, 2021 9:50:27 GMT -5
afrezzahcp.comMany times on the afrezza page that comes up, at the top of the page is a link for health care providers. afrezza.comthere it is on the top of the page, healthcare professional site. Providers know there are links to the professional sites on the medication website. Heck, I knew it. Well heck I knew it too. But how are they getting it to the right audience? I knew you knew it. In nursing and medical school, I believe we are all told, the medical professional is responsible to know the medications they prescribe, give. In is in the Standards of care. The answer, it is their job to know. The profession has standards. |
|
Buy all the cheap shares you can !!!
